Search the Newsreel

Radiopharm Theranostics (ASX:RAD) Advances Funding Plans with New Share Offer

Radiopharm Theranostics (ASX:RAD) has initiated a Security Purchase Plan (SPP) allowing eligible shareholders to acquire new shares at AUD 0.015 each or a 2.5% discount to VWAP. Shareholders on record by July 23, 2026, can apply for up to AUD 100,000 worth of shares, …

Radiopharm Theranostics Amends SPP to Reflect Maximum Issue of AUD10 Million Including Oversubscriptions

Radiopharm Theranostics Limited (ASX:RAD) has amended its securities purchase plan (SPP) to allow for a maximum issue of AUD10 million, which includes AUD4 million in oversubscriptions. This revision, updated from a previous filing on July 24, 2026, permits the issuance of up to 666,666,667 …

Radiopharm Theranostics to Issue 848.8 Million Free Attaching Options Exercisable at $0.018

Radiopharm Theranostics Limited (ASX:RAD) is set to issue approximately 848.8 million free attaching options, exercisable at $0.018 each and expiring on July 31, 2029. These options are part of a share offer under a prospectus dated July 30, 2026, and are subject to shareholder …

Press Release: Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics (ASX: RAD) provided a business update highlighting the successful completion of a A$5.5 million capital raise and significant progress in its clinical trials. The company is advancing multiple radiopharmaceutical programs for cancer treatment, including promising results from its Phase II trial for …

RADX Stock Price and Chart — NASDAQ:RADX

This page provides an overview of Radiopharm Theranostics Limited (RADX) stock, traded on the Nasdaq Stock Market. It includes key financial statistics such as market capitalization, revenue, and net income, alongside stock performance metrics over various periods. The company, founded in 2021, focuses on …

Regal-backed biotech Radiopharm Theranostics seeks $16m

Radiopharm Theranostics, a clinical-stage biotech supported by Regal, is seeking to raise $16 million from investors. The funds will be used to finance drug manufacturing and future clinical trials for its cancer-diagnosing and treating drugs. Paul Hopper is the chairman of the company.

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

Radiopharm Theranostics has announced a concurrent US$4.1 million registered direct offering to US institutional investors, involving the issuance of American Depositary Shares and warrants. Additionally, the company is undertaking an Australian Placement of A$6.7 million and a Share Purchase Plan for up to an …

Radiopharm stock tumbles 21% on dilutive capital raise

Radiopharm Theranostics Ltd ADR (NASDAQ: RADX) shares dropped 21% after announcing a plan to raise up to $13 million through concurrent U.S. and Australian offerings. The clinical-stage biopharmaceutical company will issue American Depositary Shares and warrants to accredited institutional investors. This capital raise is …

Radiopharm Theranostics (Nasdaq: RADX) plans US$4.1M ADS sale plus A$12.7M raise

Radiopharm Theranostics is undertaking a capital raise through a US registered direct offering of American Depositary Shares (ADSs) to secure approximately US$4.1 million, alongside a concurrent private placement of unregistered warrants. Additionally, the company is raising A$6.7 million from Australian investors, with a potential …

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

Radiopharm Theranostics announced positive Phase 2b trial results for RAD101, an imaging agent for diagnosing brain metastases, showing 93% concordance with MRI. The company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026, targeting a $600+ million market with …

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

Radiopharm Theranostics announced positive initial data from its Phase 1 clinical trial of RAD204, an investigational PD-L1-targeted radiotherapeutic, for advanced solid tumors. The study observed a confirmed durable partial response in one patient, who remained progression-free for over seven months, and early tumor shrinkage …

Radiopharm Theranostics reports positive results in tumour trials

Radiopharm Theranostics announced positive results from its Phase 2b trial of RAD101, a PET tracer for recurrent brain metastases, showing 93% concordance with MRI and demonstrating potential for diagnostic clarity. The company also provided an update on its RAD204 radiotherapeutic, noting a partial response …

Radiopharm Theranostics (RADX) Institutional Ownership 2026

Tesla, iRobot, ServiceNow, Radiopharm Theranostics, Kyverna Therapeutics: Stocks Making The Biggest Moves Today

Radiopharm Theranostics Surge: Buy or Sell?

RADX SEC Filings - Radiopharm Theranostics Ltd 10-K, 10-Q, 8-K Forms

Radiopharm Theranostics (RADX) Stock Forecast and Price Target 2026

Radiopharm Theranostics (RADX) Stock Price, News & Analysis